Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C20H24N2O2.C6H8O7 |
Molecular Weight | 840.957 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC(O)(CC(O)=O)C(O)=O.COC1=CC=C2N=CC=C([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1.COC5=CC=C6N=CC=C([C@@H](O)[C@@H]7C[C@@H]8CC[N@]7C[C@@H]8C=C)C6=C5
InChI
InChIKey=YSFIPRFOHJQXJF-VMJVVOMYSA-N
InChI=1S/2C20H24N2O2.C6H8O7/c2*1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;7-3(8)1-6(13,5(11)12)2-4(9)10/h2*3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t2*13-,14-,19-,20+;/m00./s1
Molecular Formula | C6H8O7 |
Molecular Weight | 192.1235 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C20H24N2O2 |
Molecular Weight | 324.4168 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021799s024lbl.pdfhttps://onlinelibrary.wiley.com/doi/abs/10.1002/jps.3080010617Curator's Comment: description was created based on several sources, including
http://www.fda.gov/downloads/ForHealthProfessionals/LearningActivities/UCM317816.pdf
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021799s024lbl.pdfhttps://onlinelibrary.wiley.com/doi/abs/10.1002/jps.3080010617
Curator's Comment: description was created based on several sources, including
http://www.fda.gov/downloads/ForHealthProfessionals/LearningActivities/UCM317816.pdf
Quinine soluble salts possess the extremely bitter taste, that may have a perplexing problem especially to children. That is why the most common combinations which are administered in this way are the sulphate, salicylate, tannate and certain esters. Quinine tannate, an insoluble quinine salt has been known in medicine for a very long time. However, many experiments have revealed that quinine tannate was practically inert as a medicinal substance.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL613897 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14967191 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | QUALAQUIN Approved Useis a cinchona alkaloid indicated for treatment of uncomplicated Plasmodium falciparum malaria Launch Date2005 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.2 μg/mL |
8.7 mg/kg single, oral dose: 8.7 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
QUININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
28 μg × h/mL |
8.7 mg/kg single, oral dose: 8.7 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
QUININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.5 h |
8.7 mg/kg single, oral dose: 8.7 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
QUININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8% |
8.7 mg/kg single, oral dose: 8.7 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
QUININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
5 g single, oral |
unhealthy, 17 years |
Other AEs: Respiratory distress... |
1.8 g single, oral Overdose |
unhealthy, 46 years |
Other AEs: Hearing loss... |
16250 mg single, oral Overdose Dose: 16250 mg Route: oral Route: single Dose: 16250 mg Sources: |
unhealthy, 49 years |
Other AEs: Cardiotoxicity... |
9.75 g single, oral |
unhealthy, adult |
Other AEs: Tachycardia... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Respiratory distress | grade 5, 1 patient | 5 g single, oral |
unhealthy, 17 years |
Hearing loss | 1 patient | 1.8 g single, oral Overdose |
unhealthy, 46 years |
Cardiotoxicity | 1 patient | 16250 mg single, oral Overdose Dose: 16250 mg Route: oral Route: single Dose: 16250 mg Sources: |
unhealthy, 49 years |
Tachycardia | grade 5 | 9.75 g single, oral |
unhealthy, adult |
PubMed
Title | Date | PubMed |
---|---|---|
Simultaneous separation of the stereoisomers of 1-amino-2-hydroxy and 2-amino-1-hydroxypropane phosphonic acids by stereoselective capillary electrophoresis employing a quinine carbamate type chiral selector. | 2001 Apr |
|
HPTLC method for the estimation of alkaloids of Cinchona officinalis stem bark and its marketed formulations. | 2001 Apr |
|
Simultaneous determination of quinine and four metabolites in plasma and urine by high-performance liquid chromatography. | 2001 Apr 15 |
|
Resurgence of blackwater fever in long-term European expatriates in Africa: report of 21 cases and review. | 2001 Apr 15 |
|
Severe babesiosis in Long Island: review of 34 cases and their complications. | 2001 Apr 15 |
|
Soa genotype selectively affects mouse gustatory neural responses to sucrose octaacetate. | 2001 Apr 27 |
|
Quinine-induced thrombocytopenia in a 64-year-old man who consumed tonic water to relieve nocturnal leg cramps. | 2001 Aug |
|
Ferrocene-chloroquine analogues as antimalarial agents: in vitro activity of ferrochloroquine against 103 Gabonese isolates of Plasmodium falciparum. | 2001 Aug |
|
Pontine gustatory activity is altered by electrical stimulation in the central nucleus of the amygdala. | 2001 Feb |
|
Activation of ion-conducting pathways in the inner mitochondrial membrane - an unrecognized activity of fatty acid? | 2001 Feb 23 |
|
Taste receptor cells that discriminate between bitter stimuli. | 2001 Feb 23 |
|
Declining chloroquine resistance of Plasmodium falciparum in Lambaréné, Gabon from 1992 to 1998. | 2001 Jan 15 |
|
Effect of extracellular Ca2+ on the quinine-activated current of bullfrog taste receptor cells. | 2001 Jan 15 |
|
The applicability of rat and human liver slices to the study of mechanisms of hepatic drug uptake. | 2001 Jan-Feb |
|
[Effect of antibodies against S100 proteins on neural plasticity in sensitized and naive snails]. | 2001 Jan-Feb |
|
Distribution of gustatory sensitivities in rat taste cells: whole-cell responses to apical chemical stimulation. | 2001 Jul 1 |
|
Therapeutic efficacy of sulphadoxine/pyrimethamine and susceptibility in vitro of P. falciparum isolates to sulphadoxine-pyremethamine and other antimalarial drugs in Malawian children. | 2001 Jun |
|
A comparison of brain, core and skin temperature in children with complicated and uncomplicated malaria. | 2001 Jun |
|
Nocturnal leg cramps. Clinically mysterious and painful--but manageable. | 2001 Jun |
|
Mechanisms by which intracellular calcium induces susceptibility to secretory phospholipase A2 in human erythrocytes. | 2001 Jun 22 |
|
Effects of hydroxypyridinone iron chelators in combination with antimalarial drugs on the in vitro growth of Plasmodium falciparum. | 2001 Mar |
|
Persistence of Plasmodium falciparum in the placenta after apparently effective quinidine/clindamycin therapy. | 2001 Mar |
|
Capillary electrophoretic separation, immunochemical recognition and analysis of the diastereomers quinine and quinidine and two quinidine metabolites in body fluids. | 2001 Mar |
|
Genomic and functional characteristics of novel human pancreatic 2P domain K(+) channels. | 2001 Mar 23 |
|
Exchange transfusion for severe malaria. | 2001 Mar-Apr |
|
Oral quinine pharmacokinetics and dietary salt intake. | 2001 May |
|
Changes in taste intensity perception following anterior temporal lobe removal in humans. | 2001 May |
|
Evaluation of the contribution to enantioselectivity of quinine and quinidine scaffolds in chemically and physically mixed chiral selectors. | 2001 May 5 |
|
Is multiple sclerosis caused by a silent infection with malarial parasites? A historico-epidemiological approach: part II. | 2001 Sep |
|
Volume-activated trimethylamine oxide efflux in red blood cells of spiny dogfish (Squalus acanthias). | 2001 Sep |
Sample Use Guides
in adults: 648 mg (two capsules) every 8 hours for 7 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27089323
Quinine (0-100 uM) stimulates adipogenesis through ERK/S6 (extracellular-signal-regulated kinase/Ribosomal protein S6) signaling, which at least partly functions via taste receptor, type 2, member 106 (T2R106)
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:51:04 GMT 2025
by
admin
on
Mon Mar 31 17:51:04 GMT 2025
|
Record UNII |
L8D5LFU229
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 310.547
Created by
admin on Mon Mar 31 17:51:04 GMT 2025 , Edited by admin on Mon Mar 31 17:51:04 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
71586768
Created by
admin on Mon Mar 31 17:51:04 GMT 2025 , Edited by admin on Mon Mar 31 17:51:04 GMT 2025
|
PRIMARY | |||
|
DBSALT002255
Created by
admin on Mon Mar 31 17:51:04 GMT 2025 , Edited by admin on Mon Mar 31 17:51:04 GMT 2025
|
PRIMARY | |||
|
L8D5LFU229
Created by
admin on Mon Mar 31 17:51:04 GMT 2025 , Edited by admin on Mon Mar 31 17:51:04 GMT 2025
|
PRIMARY | |||
|
100000078601
Created by
admin on Mon Mar 31 17:51:04 GMT 2025 , Edited by admin on Mon Mar 31 17:51:04 GMT 2025
|
PRIMARY | |||
|
SUB15089MIG
Created by
admin on Mon Mar 31 17:51:04 GMT 2025 , Edited by admin on Mon Mar 31 17:51:04 GMT 2025
|
PRIMARY | |||
|
752-72-7
Created by
admin on Mon Mar 31 17:51:04 GMT 2025 , Edited by admin on Mon Mar 31 17:51:04 GMT 2025
|
PRIMARY | |||
|
DTXSID10226178
Created by
admin on Mon Mar 31 17:51:04 GMT 2025 , Edited by admin on Mon Mar 31 17:51:04 GMT 2025
|
PRIMARY | |||
|
212-037-1
Created by
admin on Mon Mar 31 17:51:04 GMT 2025 , Edited by admin on Mon Mar 31 17:51:04 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |